Abstract
Angiogenesis is crucial to the growth of malignant gliomas. Therefore, antiangiogenic therapy represents a new, promising therapeutic modality for malignant gliomas. This study was designed to define the malignant glioma cases most suitable for antiangiogenic therapy in humans and to demonstrate the efficacy of antiangiogenic therapy in animals. Protein expression of the most potent angiogenic factor, vascular endothelial growth factor (VEGF), and its specific natural inhibitor, soluble Flt-1, as well as vessel architecture, including vessel density, area, and diameter, was evaluated in human malignant glioma samples (24 glioblastomas, 13 anaplastic astrocytomas). Among these, VEGF >1000ng/ml, VEGF/soluble Fltl ratio >1, vessel density >30, and vessel area >7% were prognostic factors for malignant gliomas. Based on these results, we per formed three different antiangiogenic experiments targeted to inhibit VEGF expression in a human malignant glioma (U87) mouse model: anti-VEGF neutralized antibody intraperitoneal injection; interferon-beta intramusclar injection; and transfection of an endogenous nonspecific angiogenesis inhibitor, thrombospondin-1, into glioma cells caused inhibition of VEGF secretion and/or mRNA expression and resulted in glioma growth inhibition of 70%, 84%, and 50%, respectively, compared with control. We conclude that malignant gliomas with high degrees of VEGF expression and vessel areas are good candidates for antiangiogenic therapy, especially that designed to inhibit VEGF expression.
Similar content being viewed by others
References
Godard S, Getz G, Delorenzi M, et al (2003) Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 63:613–6625
Jensen RL (1998) Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol 49:189–196
Zagzag D, Amirnovin R, Greco MA, et al (2000) Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 80:837–849
Lund E, Spang-Thomsen M, Skovgaard-Poulsen H, et al (1998) Tumor angiogenesis — a new therapeutic target in gliomas. Acta Neurol Scand 97:52–62
Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nature Rev Cancer 2:727–739
Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364
Kirsch M, Strasser J, Allende R, et al (1998) Angiostatin suppresses malignant glioma growth in vivo. Cancer Res 58:4654–4659
Reed TA, Sorensen DR, Mahesparan R, et al (2001) Local endostatin treatment of gliomas administered by microcapsulated producer cells. Nat Biotechnol 19:29–34
Takano S, Tsuboi K, Matsumura A, et al (2003) Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumor growth and angiogenesis in human glioblastoma xenografts. Neurooncol 5:1–7
Takano S, Yoshii Y, Kondo S, et al (1996) Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 56:2185–2190
Lamszus K, Ulbricht U, Matschke J, et al (2003) Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res 9:1399–1405
Yang JC, Haworth L, Sherry RM, et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434
Bocci G, Francia G, Man S, et al (2003) Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronic chemotherapy. Proc Natl Acad Sci USA 100:12917–12922
Tanaka T, Cao Y, Folkman J, et al (1998) Viral vector mediated “anti-angiogenic” gene therapy utilizing angiostatin cDNA. Cancer Res 58:3362–3369
Yoshida JA, Kajita T, Wakabayashi T, et al (1994) Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir (Wien) 127:55–59
Yoshida J, Mizuno M, Fujii M, et al (2004) Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes. Hum Gene Ther 15:77–86
Singh RK, Gutman M, Bucana CD, et al (1995) Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 92:4562–4566
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Takano, S., Kamiyama, H., Tsuboi, K. et al. Angiogenesis and antiangiogenic therapy for malignant gliomas. Brain Tumor Pathol 21, 69–73 (2004). https://doi.org/10.1007/BF02484513
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02484513